Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985;15(1):16-9.
doi: 10.1007/BF00257287.

Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns

Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns

T Tsuruo et al. Cancer Chemother Pharmacol. 1985.

Abstract

The calcium channel blockers verapamil, diltiazem, nicardipine, and niludipine potentiated the antitumor activities of mitotic poison antitumor agents, such as vincristine, vinblastine, vindesine, VP16-213, and taxol in P388 leukemia cells resistant to vincristine. The potentiating effect was generally dependent on the extent of cross-resistance seen in the cell line for these drugs. Calcium channel blockers also potentiate the antitumor activities of several DNA-interacting drugs, such as adriamycin, THP-adriamycin, daunomycin, aclacinomycin A, mitomycin C, actinomycin D, mitoxantrone, and nogalamycin derivatives in P388 leukemia resistant to adriamycin. Greater potentiation was observed for those antitumor agents to which the ADM-resistant cell line had become markedly cross-resistant, with the exception of the nogalamycin derivatives. Only a two-fold enhancement was observed for mitomycin C and aclacinomycin, as the cell line was only weakly cross-resistant to these agents. These results suggest the potential for therapeutic gain through the use of calcium channel blockers in combination with classic chemotherapeutic agents.

PubMed Disclaimer

References

    1. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1971-8 - PubMed
    1. Cancer Res. 1979 Jun;39(6 Pt 1):2200-3 - PubMed
    1. Cancer Res. 1978 Dec;38(12):4722-7 - PubMed
    1. Cancer Res. 1983 Jun;43(6):2905-10 - PubMed
    1. Cancer Res. 1982 Nov;42(11):4730-3 - PubMed

Publication types

LinkOut - more resources